Wedbush Maintains Outperform on Janux Therapeutics, Lowers Price Target to $36

Benzinga Newsdesk www.benzinga.com Negative 93.5%

Neg 93.5% Neu 0% Pos 0%

Wedbush analyst Robert Driscoll maintains Janux Therapeutics (NASDAQ:JANX) with a Outperform and lowers the price target from $45 to $36.